Literature DB >> 18991276

Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype.

Nina Hillen1, Gabor Mester, Claudia Lemmel, Andreas O Weinzierl, Margret Müller, Dorothee Wernet, Jörg Hennenlotter, Arnulf Stenzl, Hans-Georg Rammensee, Stefan Stevanović.   

Abstract

Human leukocyte antigens (HLA) have long been grouped into supertypes to facilitate peptide-based immunotherapy. Analysis of several hundreds of peptides presented by all nine antigens of the HLA-B44 supertype (HLA-B*18, B*37, B*40, B*41, B*44, B*45, B*47, B*49 and B*50) revealed unique peptide motifs for each of them. Taking all supertype members into consideration only 25 out of 670 natural ligands were found on more than one HLA molecule. Further direct comparisons by two mass spectrometric methods--isotope labeling as well as a label-free approach--consistently demonstrated only minute overlaps of below 3% between the ligandomes of different HLA antigens. In addition, T cell reactions of healthy donors against immunodominant HLA-B*44 and HLA-B*40 epitopes from EBV lacked promiscuous T-cell recognition within the HLA-B44 supertype. Taken together, these results challenge the common paradigm of broadly presented epitopes within this supertype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991276     DOI: 10.1002/eji.200838632

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  Position 45 influences the peptide binding motif of HLA-B*44:08.

Authors:  Soumya Badrinath; Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2011-10-19       Impact factor: 2.846

2.  Residue 81 confers a restricted C-terminal peptide binding motif in HLA-B*44:09.

Authors:  Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2012-06-16       Impact factor: 2.846

Review 3.  MHC class II epitope predictive algorithms.

Authors:  Morten Nielsen; Ole Lund; Søren Buus; Claus Lundegaard
Journal:  Immunology       Date:  2010-04-12       Impact factor: 7.397

Review 4.  Major histocompatibility complex class I binding predictions as a tool in epitope discovery.

Authors:  Claus Lundegaard; Ole Lund; Søren Buus; Morten Nielsen
Journal:  Immunology       Date:  2010-05-26       Impact factor: 7.397

5.  Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.

Authors:  Miguel Marcilla; Adán Alpízar; Manuel Lombardía; Antonio Ramos-Fernandez; Manuel Ramos; Juan Pablo Albar
Journal:  Mol Cell Proteomics       Date:  2013-12-23       Impact factor: 5.911

Review 6.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

7.  The Behçet's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing.

Authors:  Pablo Guasp; Eilon Barnea; M Francisca González-Escribano; Anaïs Jiménez-Reinoso; José R Regueiro; Arie Admon; José A López de Castro
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

8.  The human leukocyte antigen-presented ligandome of B lymphocytes.

Authors:  Chopie Hassan; Michel G D Kester; Arnoud H de Ru; Pleun Hombrink; Jan Wouter Drijfhout; Harm Nijveen; Jack A M Leunissen; Mirjam H M Heemskerk; J H Frederik Falkenburg; Peter A van Veelen
Journal:  Mol Cell Proteomics       Date:  2013-03-12       Impact factor: 5.911

9.  HLA Class I Supertype Associations With Clinical Outcome of Secondary Dengue Virus Infections in Ethnic Thais.

Authors:  Sasijit Vejbaesya; Rungrot Thongpradit; Siripen Kalayanarooj; Komon Luangtrakool; Panpimon Luangtrakool; Robert V Gibbons; Duangporn Srinak; Somporn Ngammthaworn; Kusuma Apisawes; In-Kyu Yoon; Stephen J Thomas; Richard G Jarman; Anon Srikiakthachorn; Sharone Green; Dasnayanee Chandanayingyong; Sangshin Park; Jennifer Friedman; Alan L Rothman; Henry A F Stephens
Journal:  J Infect Dis       Date:  2015-03-04       Impact factor: 5.226

10.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Authors:  Diego Chowell; Luc G T Morris; Claud M Grigg; Jeffrey K Weber; Robert M Samstein; Vladimir Makarov; Fengshen Kuo; Sviatoslav M Kendall; David Requena; Nadeem Riaz; Benjamin Greenbaum; James Carroll; Edward Garon; David M Hyman; Ahmet Zehir; David Solit; Michael Berger; Ruhong Zhou; Naiyer A Rizvi; Timothy A Chan
Journal:  Science       Date:  2017-12-07       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.